VIVUS PE Ratio 2006-2019 | VVUS

Current and historical p/e ratio for VIVUS (VVUS) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. VIVUS PE ratio as of November 08, 2019 is 0.00.
VIVUS PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-11-11 2.75 0.00
2019-09-30 3.86 $-1.73 0.00
2019-06-30 3.82 $-2.60 0.00
2019-03-31 4.20 $-3.24 0.00
2018-12-31 2.23 $-3.49 0.00
2018-09-30 4.41 $-4.07 0.00
2018-06-30 7.05 $-3.80 0.00
2018-03-31 3.56 $-3.90 0.00
2017-12-31 5.03 $-3.00 0.00
2017-09-30 9.90 $3.40 2.91
2017-06-30 12.20 $3.10 3.94
2017-03-31 11.20 $3.30 3.39
2016-12-31 11.50 $2.20 5.23
2016-09-30 11.40 $-4.40 0.00
2016-06-30 11.20 $-5.00 0.00
2016-03-31 14.00 $-8.70 0.00
2015-12-31 10.20 $-9.00 0.00
2015-09-30 16.40 $-10.30 0.00
2015-06-30 23.60 $-10.30 0.00
2015-03-31 24.60 $-8.00 0.00
2014-12-31 28.80 $-8.00 0.00
2014-09-30 38.60 $-7.20 0.00
2014-06-30 53.20 $-10.50 0.00
2014-03-31 59.40 $-13.50 0.00
2013-12-31 90.80 $-17.30 0.00
2013-09-30 93.00 $-21.20 0.00
2013-06-30 125.80 $-20.40 0.00
2013-03-31 110.00 $-17.30 0.00
2012-12-31 134.20 $-14.00 0.00
2012-09-30 178.10 $-9.70 0.00
2012-06-30 285.40 $-6.70 0.00
2012-03-31 223.60 $-6.30 0.00
2011-12-31 97.50 $-5.50 0.00
2011-09-30 80.70 $-5.00 0.00
2011-06-30 81.40 $-6.20 0.00
2011-03-31 61.90 $-7.00 0.00
2010-12-31 93.70 $-8.10 0.00
2010-09-30 66.90 $-8.90 0.00
2010-06-30 96.00 $-9.70 0.00
2010-03-31 87.30 $-8.80 0.00
2009-12-31 92.00 $-7.50 0.00
2009-09-30 104.20 $-6.90 0.00
2009-06-30 60.80 $-3.90 0.00
2009-03-31 43.20 $-1.40 0.00
2008-12-31 53.20 $-1.60 0.00
2008-09-30 79.40 $1.10 72.18
2008-06-30 66.80 $1.30 51.38
2008-03-31 60.30 $-0.40 0.00
2007-12-31 51.80 $-0.50 0.00
2007-09-30 49.60 $-2.40 0.00
2007-06-30 52.30 $-3.90 0.00
2007-03-31 51.30 $-4.00 0.00
2006-12-31 36.20 $-4.70 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.031B $0.065B
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $131.380B 15.13
Gilead Sciences (GILD) United States $82.715B 10.25
CSL (CSLLY) Australia $82.366B 0.00
Celgene (CELG) United States $77.961B 11.13
Biogen (BIIB) United States $52.915B 9.08
Vertex Pharmaceuticals (VRTX) United States $51.767B 52.84
Illumina (ILMN) United States $43.128B 47.32
Regeneron Pharmaceuticals (REGN) United States $37.539B 16.43
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $24.517B 12.11
Seattle Genetics (SGEN) United States $18.568B 0.00
Incyte (INCY) United States $18.330B 42.55
SINO PHARMACEUT (SBMFF) Hong Kong, SAR China $18.254B 0.00
BioMarin Pharmaceutical (BMRN) United States $13.634B 0.00
Genmab (GNMSF) Denmark $13.346B 74.86
Exact Sciences (EXAS) United States $10.862B 0.00
Bio-Rad Laboratories (BIO.B) United States $10.393B 49.88
Alnylam Pharmaceuticals (ALNY) United States $10.372B 0.00
Galapagos (GLPG) Belgium $10.348B 26.66
BeiGene (BGNE) Cayman Islands $9.470B 0.00
Bio-Techne Corp (TECH) United States $7.745B 51.84
Sarepta Therapeutics (SRPT) United States $7.177B 0.00
QIAGEN (QGEN) Netherlands $7.128B 23.24
Guardant Health (GH) United States $6.683B 0.00
ACADIA Pharmaceuticals (ACAD) United States $6.563B 0.00
Reata Pharmaceuticals (RETA) United States $6.370B 0.00
Amarin (AMRN) Ireland $6.244B 0.00
Moderna (MRNA) United States $5.829B 0.00
Horizon Therapeutics Public (HZNP) Ireland $5.525B 14.05
ARGENX SE-ADR (ARGX) Netherlands $4.861B 0.00
Exelixis (EXEL) United States $4.792B 13.48
Ascendis Pharma (ASND) Denmark $4.780B 0.00
China Biologic Products (CBPO) China $4.566B 28.50
Medicines (MDCO) United States $4.386B 0.00
Repligen (RGEN) United States $4.378B 79.33
Bluebird Bio (BLUE) United States $4.314B 0.00
Spark Therapeutics (ONCE) United States $4.294B 0.00
Mirati Therapeutics (MRTX) United States $4.132B 0.00
Blueprint Medicines (BPMC) United States $3.605B 0.00
Adaptive Biotechnologies (ADPT) United States $3.429B 0.00
MorphoSys AG (MOR) Germany $3.410B 0.00
Immunomedics (IMMU) United States $3.376B 0.00
Alkermes (ALKS) Ireland $3.168B 0.00
Genmab (GMAB) Denmark $2.843B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.790B 0.00
Emergent Biosolutions (EBS) United States $2.790B 27.71
MyoKardia (MYOK) United States $2.774B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.709B 0.00
Halozyme Therapeutics (HALO) United States $2.468B 0.00
Genomic Health (GHDX) United States $2.385B 44.36
Arena Pharmaceuticals (ARNA) United States $2.362B 5.52
NeoGenomics (NEO) United States $2.357B 126.06
UniQure (QURE) Netherlands $2.339B 0.00
Acceleron Pharma (XLRN) United States $2.297B 0.00
Amicus Therapeutics (FOLD) United States $2.276B 0.00
Ultragenyx Pharmaceutical (RARE) United States $2.247B 0.00
RA PHARMCTL INC (RARX) United States $2.201B 0.00
Zai Lab (ZLAB) China $2.185B 0.00
Ligand Pharmaceuticals (LGND) United States $2.068B 36.76
Cambrex (CBM) United States $2.017B 25.45
Akcea Therapeutics (AKCA) United States $1.813B 0.00
Myriad Genetics (MYGN) United States $1.759B 25.98
Insmed (INSM) United States $1.704B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.623B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $1.519B 0.00
REGENXBIO (RGNX) United States $1.468B 0.00
Denali Therapeutics (DNLI) United States $1.423B 0.00
Epizyme (EPZM) United States $1.383B 0.00
Zymeworks (ZYME) Canada $1.349B 0.00
Coherus BioSciences (CHRS) United States $1.330B 0.00
Innoviva (INVA) United States $1.266B 3.73
Dicerna Pharmaceuticals (DRNA) United States $1.211B 0.00
Alector (ALEC) United States $1.178B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.145B 0.00
Zealand Pharma (ZLDPF) Denmark $1.143B 0.00
Sangamo Therapeutics (SGMO) United States $1.142B 0.00
Fate Therapeutics (FATE) United States $1.104B 0.00
Zealand Pharma (ZEAL) Denmark $1.025B 11.50
Editas Medicine (EDIT) United States $1.015B 0.00
WAVE Life Sciences (WVE) Singapore $0.950B 0.00
Athenex (ATNX) United States $0.923B 0.00
Codexis (CDXS) United States $0.907B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.891B 0.00
Arvinas (ARVN) United States $0.861B 0.00
Anika Therapeutics (ANIK) United States $0.859B 27.88
Cara Therapeutics (CARA) United States $0.848B 0.00
Vericel (VCEL) United States $0.840B 313.33
ZIOPHARM Oncology Inc (ZIOP) United States $0.804B 0.00
Pharming Group (PHGUF) Netherlands $0.799B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.786B 6.61
Principia Biopharma (PRNB) United States $0.764B 0.00
Twist Bioscience (TWST) United States $0.735B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.734B 0.00
Heska (HSKA) United States $0.717B 183.16
Revance Therapeutics (RVNC) United States $0.699B 0.00
DBV Technologies S.A (DBVT) France $0.696B 0.00
ANI Pharmaceuticals (ANIP) United States $0.694B 11.83
MiMedx (MDXG) United States $0.652B 0.00
Intellia Therapeutics (NTLA) United States $0.643B 0.00
Mesoblast (MESO) Australia $0.602B 0.00
GENFIT S.A (GNFT) France $0.588B 0.00
Adverum Biotechnologies (ADVM) United States $0.563B 0.00
Cellectis S.A (CLLS) France $0.555B 0.00
Retrophin (RTRX) United States $0.552B 0.00
Intra-Cellular Therapies (ITCI) United States $0.529B 0.00
BioDelivery Sciences (BDSI) United States $0.518B 0.00
UROGEN PHARMA (URGN) United States $0.492B 0.00
Agenus (AGEN) United States $0.490B 0.00
Cytokineticsorporated (CYTK) United States $0.484B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.484B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.477B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.473B 0.00
PHARMA MAR SA (PHMMF) Spain $0.465B 0.00
Sinovac Biotech (SVA) China $0.460B 0.00
Precision BioSciences (DTIL) United States $0.456B 0.00
Stemline Therapeutics (STML) United States $0.407B 0.00
Kadmon Holdings (KDMN) United States $0.390B 0.00
AC Immune SA (ACIU) Switzerland $0.380B 28.15
Lexicon Pharmaceuticals (LXRX) United States $0.374B 2.59
Merus (MRUS) Netherlands $0.367B 0.00
Prothena (PRTA) Ireland $0.362B 0.00
Puma Biotechnology (PBYI) United States $0.346B 0.00
Arcus Biosciences (RCUS) United States $0.346B 0.00
Bellus Health (BLU) Canada $0.344B 0.00
Dynavax Technologies (DVAX) United States $0.343B 0.00
Kindred Biosciences (KIN) United States $0.342B 0.00
Cellular Biomedicine (CBMG) United States $0.341B 0.00
PDL BioPharma (PDLI) United States $0.332B 8.31
Clovis Oncology (CLVS) United States $0.322B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.318B 0.00
Starpharma Holdings (SPHRY) Australia $0.308B 0.00
Theratechnologies (THTX) Canada $0.304B 0.00
Geron (GERN) United States $0.296B 0.00
Avid Bioservices (CDMO) United States $0.290B 0.00
Gritstone Oncology (GRTS) United States $0.279B 0.00
Compugen (CGEN) Israel $0.277B 0.00
AnaptysBio (ANAB) United States $0.275B 0.00
Protagonist Therapeutics (PTGX) United States $0.275B 0.00
CytomX Therapeutics (CTMX) United States $0.270B 0.00
Scholar Rock Holding (SRRK) United States $0.267B 0.00
Seres Therapeutics (MCRB) United States $0.258B 0.00
ADMA Biologics Inc (ADMA) United States $0.256B 0.00
Sutro Biopharma (STRO) United States $0.254B 0.00
Biofrontera AG (BFRA) Germany $0.253B 378.53
Inovio Pharmaceuticals (INO) United States $0.250B 0.00
Albireo Pharma (ALBO) United States $0.240B 0.00
MannKind (MNKD) United States $0.239B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.233B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.230B 0.00
Syros Pharmaceuticals (SYRS) United States $0.221B 0.00
Sorrento Therapeutics (SRNE) United States $0.220B 0.00
Kamada (KMDA) Israel $0.213B 8.15
POXEL SA FRANCE (PXXLF) France $0.213B 0.00
XOMA (XOMA) United States $0.210B 0.00
OSMOTICA PHARM (OSMT) United States $0.206B 0.00
Cue Biopharma (CUE) United States $0.203B 0.00
Spero Therapeutics (SPRO) United States $0.201B 0.00
Athersys (ATHX) United States $0.199B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.193B 0.00
Exicure (XCUR) United States $0.189B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.189B 0.00
Senesco Technologies (ELOX) United States $0.179B 0.00
ChromaDex (CDXC) United States $0.173B 0.00
Arsanis (XFOR) United States $0.167B 0.00
Dyadic (DYAI) United States $0.161B 0.00
Affimed (AFMD) Germany $0.160B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.157B 0.00
Nicox SA (NICXF) France $0.150B 0.00
Bicycle Therapeutics (BCYC) United Kingdom $0.150B 0.00
Cerecor (CERC) United States $0.149B 0.00
Prometic Life Sciences (PFSCF) Canada $0.146B 0.00
Ophthotech (ISEE) United States $0.145B 0.00
Enzo Biochem (ENZ) United States $0.144B 0.00
Five Prime Therapeutics (FPRX) United States $0.142B 0.00
Alcobra (ARCT) United States $0.140B 0.00
Emmaus Life Sciences (EMMA) United States $0.136B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.133B 0.00
Northwest Biotherapeutics (NWBO) United States $0.131B 0.00
Abeona Therapeutics (ABEO) United States $0.130B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.129B 0.00
Menlo Therapeutics (MNLO) United States $0.125B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.117B 0.00
SESEN BIO, INC (SESN) United States $0.115B 0.00
PHASEBIO PHARMA (PHAS) United States $0.114B 0.00
Acorda Therapeutics (ACOR) United States $0.112B 0.00
NantKwest (NK) United States $0.110B 0.00
Novavax (NVAX) United States $0.110B 0.00
Aptinyx (APTX) United States $0.108B 0.00
OvaScience (MLND) United States $0.104B 0.00
Windtree Therapeutics (WINT) United States $0.103B 0.00
Mersana Therapeutics (MRSN) United States $0.100B 0.00
Fortress Biotech (FBIO) United States $0.099B 0.00
VBI Vaccines (VBIV) United States $0.099B 0.00
Aduro Biotech (ADRO) United States $0.095B 0.00
Strongbridge Biopharma (SBBP) United States $0.095B 2.54
Adaptimmune Therapeutics (ADAP) United Kingdom $0.093B 0.00
Antibe Therapeutics (ATBPF) Canada $0.088B 0.00
Celyad SA (CYAD) Belgium $0.088B 0.00
Adocia (ADOCY) France $0.086B 0.00
Aquinox Pharmaceuticals (NLTX) Canada $0.083B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.082B 0.00
VTv Therapeutics (VTVT) United States $0.082B 0.00
Arbutus Biopharma (ABUS) Canada $0.081B 0.00
Verastem (VSTM) United States $0.081B 0.00
Vaccinex (VCNX) United States $0.081B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.079B 0.00
ARAVIVE, INC (ARAV) United States $0.074B 0.00
Prima BioMed (IMMP) Australia $0.074B 0.00
Synlogic (SYBX) United States $0.073B 0.00
Trevena (TRVN) United States $0.070B 0.00
Idera Pharmaceuticals (IDRA) United States $0.069B 0.00
Catalyst Biosciences (CBIO) United States $0.069B 0.00
Checkpoint Therapeutics (CKPT) United States $0.068B 0.00
Liquidia Technologies (LQDA) United States $0.067B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.067B 0.00
Selecta Biosciences (SELB) United States $0.062B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.060B 0.00
Orgenesis (ORGS) United States $0.058B 21.18
NewLink Genetics (NLNK) United States $0.057B 0.00
Applied Genetic Technologies (AGTC) United States $0.056B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.053B 0.00
Pluristem Therapeutics (PSTI) Israel $0.053B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.052B 0.00
China Health Industries Holdings (CHHE) China $0.052B 15.78
Organovo Holdings (ONVO) United States $0.051B 0.00
Curis (CRIS) United States $0.049B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.049B 0.00
AquaBounty Technologies (AQB) United States $0.048B 0.00
VistaGen Therapeutics (VTGN) United States $0.047B 0.00
Vascular Biogenics (VBLT) Israel $0.047B 0.00
Proteostasis Therapeutics (PTI) United States $0.046B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.046B 0.00
AIT Therapeutics (XAIR) United States $0.045B 0.00
Clearside Biomedical (CLSD) United States $0.043B 0.00
Evogene (EVGN) Israel $0.041B 0.00
Unum Therapeutics (UMRX) United States $0.039B 0.00
Stellar Biotechnologies (EDSA) Canada $0.037B 0.00
DiaMedica Therapeutics (DMAC) United States $0.036B 0.00
Celldex Therapeutics (CLDX) United States $0.036B 0.00
Oncobiologics (OTLK) United States $0.035B 0.00
Celsion (CLSN) United States $0.031B 0.00
INNOVATE BIOPHARMACEUTICALS, INC (INNT) United States $0.030B 0.00
Aptevo Therapeutics (APVO) United States $0.030B 0.00
BioCardia (BCDA) United States $0.029B 0.00
Fibrocell Science Inc (FCSC) United States $0.029B 9.95
Entera Bio (ENTX) Israel $0.028B 0.00
Bionano Genomics (BNGO) United States $0.023B 0.00
Caladrius Biosciences (CLBS) United States $0.022B 0.00
Signal Genetics (MGEN) United States $0.022B 0.00
Apricus Biosciences (SEEL) United States $0.022B 0.00
Aerpio Pharmaceuticals (ARPO) United States $0.022B 0.00
Soligenix (SNGX) United States $0.021B 0.00
AEterna Zentaris (AEZS) United States $0.021B 0.00
Aytu Bioscience (AYTU) United States $0.021B 0.00
Novogen (KZIA) Australia $0.018B 0.00
Alimera Sciences (ALIM) United States $0.018B 0.00
Pulmatrix (PULM) United States $0.016B 0.00
CollPlant Holdings (CLGN) Israel $0.015B 0.00
TOCAGEN INC (TOCA) United States $0.015B 0.00
Prana Biotechnology (ATHE) Australia $0.015B 0.00
IMMURON (IMRN) Australia $0.014B 0.00
MYOS RENS Technology (MYOS) United States $0.012B 0.00
TRACON Pharmaceuticals (TCON) United States $0.012B 0.00
TrovaGene (TROV) United States $0.011B 0.00
Cesca Therapeutics (THMO) United States $0.011B 0.00
Titan Pharmaceuticals (TTNP) United States $0.009B 0.00
Genetic Technologies (GENE) Australia $0.009B 0.00
Benitec Biopharma (BNTC) Australia $0.008B 0.00
Cleveland BioLabs (CBLI) United States $0.007B 0.00
Cyclacel Pharmaceuticals (CYCC) United States $0.007B 0.00
Advaxis (ADXS) United States $0.006B 0.00
Neuralstem (SNCA) United States $0.002B 0.00